LabCorp Clinical Trials Announces Strategic Alliance with David H. Murdock Research Institute to offer Specialized Biomarker and Assay Development Services

September 6, 2011

Company News Release

Esoterix Clinical Trials Services

, a division of Laboratory Corporation of America Holdings (LabCorp) announced a strategic alliance with the David H. Murdock Research Institute (DHMRI) to provide its clients with access to enhanced assay development services. Assays developed at DHMRI for contracted research will be transferred to LabCorp Clinical Trials laboratories worldwide to support global clinical studies. The agreement also provides a mechanism for downstream commercialization of companion diagnostics and other biomarker assays once clinical validation has been established.
 
“With the addition of DHMRI’s discovery capabilities, LabCorp offers its clinical trials clients the most complete suite of biomarker development tools in the industry,” said Dr. David Johnston, Senior Vice President and Global Head of Clinical Trials at LabCorp. “Our collaboration with DHMRI exemplifies our strong commitment to providing cutting-edge services to our clients,” said Dr. Johnston.
 
The services available to clients through DHMRI include broad biomarker discovery and proof of concept assay development to support early and late stage drug discovery and development. DHMRI uses trans-disciplinary approaches to provide solutions for customers. DHMRI has capabilities and expertise ranging from profiling at the genetic, biochemical, cellular and in vivo levels to clinical immune system monitorin

Related Content:

News